[go: up one dir, main page]

NO20034689L - Farmasöytiske doseringsformer av amorf nelfinavir mesylat - Google Patents

Farmasöytiske doseringsformer av amorf nelfinavir mesylat

Info

Publication number
NO20034689L
NO20034689L NO20034689A NO20034689A NO20034689L NO 20034689 L NO20034689 L NO 20034689L NO 20034689 A NO20034689 A NO 20034689A NO 20034689 A NO20034689 A NO 20034689A NO 20034689 L NO20034689 L NO 20034689L
Authority
NO
Norway
Prior art keywords
dosage forms
pharmaceutical dosage
nelfinavir mesylate
amorphous nelfinavir
amorphous
Prior art date
Application number
NO20034689A
Other languages
English (en)
Other versions
NO20034689D0 (no
Inventor
Martin Howard Infeld
Wantanee Phuapradit
Navnit Hargovindas Shah
Lin Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20034689L publication Critical patent/NO20034689L/no
Publication of NO20034689D0 publication Critical patent/NO20034689D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20034689A 2001-05-03 2003-10-20 Farmasöytiske doseringsformer av amorf nelfinavir mesylat NO20034689D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (2)

Publication Number Publication Date
NO20034689L true NO20034689L (no) 2003-10-20
NO20034689D0 NO20034689D0 (no) 2003-10-20

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034689A NO20034689D0 (no) 2001-05-03 2003-10-20 Farmasöytiske doseringsformer av amorf nelfinavir mesylat

Country Status (36)

Country Link
US (1) US7014866B2 (no)
EP (1) EP1390063B1 (no)
JP (1) JP4101661B2 (no)
KR (1) KR100554816B1 (no)
CN (1) CN1255185C (no)
AR (1) AR034320A1 (no)
AT (1) ATE282428T1 (no)
BG (1) BG108311A (no)
BR (1) BR0209325A (no)
CA (1) CA2444116C (no)
CZ (1) CZ20033211A3 (no)
DE (1) DE60201988T2 (no)
EA (1) EA006627B1 (no)
EC (1) ECSP034827A (no)
ES (1) ES2231717T3 (no)
GE (1) GEP20053466B (no)
GT (1) GT200200079A (no)
HR (1) HRP20030873B1 (no)
HU (1) HU229938B1 (no)
IL (2) IL158306A0 (no)
IS (1) IS7010A (no)
JO (1) JO2401B1 (no)
MA (1) MA27018A1 (no)
MX (1) MXPA03009971A (no)
MY (1) MY128509A (no)
NO (1) NO20034689D0 (no)
NZ (1) NZ528689A (no)
PA (1) PA8544501A1 (no)
PE (1) PE20021159A1 (no)
PL (1) PL366998A1 (no)
PT (1) PT1390063E (no)
RS (1) RS83503A (no)
SK (1) SK14572003A3 (no)
TW (1) TWI234461B (no)
UA (1) UA76463C2 (no)
WO (1) WO2002089835A2 (no)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
CN100475209C (zh) * 2003-07-15 2009-04-08 阿利健制药有限公司 抗冠状病毒剂
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2548376A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
AU2005311652B2 (en) * 2004-12-03 2010-12-02 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
JP5523706B2 (ja) 2005-09-23 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規投薬配合物
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
CA2660374A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
EP2136637B1 (en) 2007-03-16 2015-11-11 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
BRPI0810362A2 (pt) * 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
WO2008137461A1 (en) 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
PT2345653E (pt) 2007-05-01 2013-04-01 Concert Pharmaceuticals Inc Compostos de morfinano
CA3056205C (en) 2007-05-01 2023-09-26 Concert Pharmaceuticals Inc. Morphinan compounds
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
RS51226B (sr) 2007-06-12 2010-12-31 Concert Pharmaceuticals Inc. Derivati azapeptida kao inhibitori hiv proteaze
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
WO2009108383A2 (en) 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
SI2334678T1 (sl) 2008-09-19 2013-05-31 Concert Pharmaceuticals Inc. Spojine morfinana
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
SI2397158T1 (sl) 2008-10-30 2016-07-29 Concert Pharmaceuticals Inc. Kombinacija spojin morfinana in antidepresivov za zdravljenje psevdobulbarnih vplivov
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US20130116239A1 (en) 2010-06-14 2013-05-09 ratiopharm GnbH Ivabradine-containing pharmaceutical composition with modified release
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
PL3235812T3 (pl) 2011-05-18 2020-04-30 Vertex Pharmaceuticals (Europe) Limited Deuterowane pochodne iwakaftoru
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
WO2013106437A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2836492B1 (en) 2012-04-13 2018-03-14 Concert Pharmaceuticals Inc. Substituted xanthine derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
BR122023027277A2 (pt) 2012-06-15 2024-01-23 Concert Pharmaceuticals, Inc. Derivados deuterados de ruxolitinib e composição farmacêutica
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
ES2700989T3 (es) 2012-12-21 2019-02-20 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
EA201892726A1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
US20160159861A1 (en) 2013-07-18 2016-06-09 Anchor Therapeutics, Inc. APJ Receptor Compounds
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
EP3177292B1 (en) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US20180044375A1 (en) 2015-03-06 2018-02-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
JP6849686B2 (ja) 2015-09-21 2021-03-24 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強剤の投与
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
BR112018011784A2 (pt) 2015-12-09 2018-12-04 Res Triangle Inst agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
AU2017261286B2 (en) 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
PT3478664T (pt) 2016-07-04 2020-12-28 Avanir Pharmaceuticals Inc Métodos para a síntese de dextrometorfano deuterado
WO2018026833A1 (en) 2016-08-01 2018-02-08 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
WO2018119076A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
US11274099B2 (en) 2017-05-19 2022-03-15 Superb Wisdom Limited Derivatives of Resiquimod
MX2020005336A (es) 2017-11-22 2020-08-13 Concert Pharmaceuticals Inc Analogos de d-serina deuterados y usos de los mismos.
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CA3136550A1 (en) 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
EP4157265A4 (en) 2020-05-27 2023-11-22 The Penn State Research Foundation ANTIBACTERIAL COMPOUNDS
WO2022094133A1 (en) 2020-10-28 2022-05-05 Concert Pharmaceuticals, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
JP2024531188A (ja) 2021-08-11 2024-08-29 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の治療
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
JP2025515051A (ja) 2022-05-04 2025-05-13 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による治療のための投与レジメン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6692767B2 (en) * 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
WO2001034118A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
PA8544501A1 (es) 2002-11-18
JP4101661B2 (ja) 2008-06-18
US20030021840A1 (en) 2003-01-30
AR034320A1 (es) 2004-02-18
EA006627B1 (ru) 2006-02-24
BR0209325A (pt) 2004-07-20
HK1070285A1 (en) 2005-06-17
HUP0401238A3 (en) 2012-09-28
MY128509A (en) 2007-02-28
EP1390063B1 (en) 2004-11-17
EA200301166A1 (ru) 2004-04-29
IL158306A0 (en) 2004-05-12
HRP20030873A2 (en) 2005-08-31
EP1390063A2 (en) 2004-02-25
WO2002089835A2 (en) 2002-11-14
MA27018A1 (fr) 2004-12-20
HRP20030873B1 (en) 2006-04-30
RS83503A (sr) 2006-10-27
PL366998A1 (en) 2005-02-07
NZ528689A (en) 2005-03-24
BG108311A (bg) 2004-12-30
IL158306A (en) 2008-11-03
NO20034689D0 (no) 2003-10-20
JO2401B1 (en) 2007-06-17
ECSP034827A (es) 2003-12-24
PE20021159A1 (es) 2002-12-20
DE60201988T2 (de) 2005-12-15
JP2004527569A (ja) 2004-09-09
GEP20053466B (en) 2005-02-25
CA2444116A1 (en) 2002-11-14
PT1390063E (pt) 2005-03-31
UA76463C2 (en) 2006-08-15
KR100554816B1 (ko) 2006-02-22
CN1547484A (zh) 2004-11-17
CN1255185C (zh) 2006-05-10
CZ20033211A3 (cs) 2004-09-15
DE60201988D1 (de) 2004-12-23
ES2231717T3 (es) 2005-05-16
HUP0401238A2 (hu) 2004-12-28
HU229938B1 (en) 2015-01-28
GT200200079A (es) 2002-12-05
TWI234461B (en) 2005-06-21
ATE282428T1 (de) 2004-12-15
US7014866B2 (en) 2006-03-21
MXPA03009971A (es) 2004-02-12
SK14572003A3 (sk) 2004-12-01
KR20040007523A (ko) 2004-01-24
WO2002089835A3 (en) 2003-05-01
CA2444116C (en) 2009-01-20
IS7010A (is) 2003-10-30

Similar Documents

Publication Publication Date Title
NO20034689D0 (no) Farmasöytiske doseringsformer av amorf nelfinavir mesylat
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
NO20033384L (no) Farmasoytisk formulering
ATE296619T1 (de) Feste orale dosierungsform von simethicon
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
NO20033785L (no) Farmasöytisk formulering
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033556L (no) Farmasöytiske formuleringer
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
EE05020B1 (et) Glburiidi ravimkoostis
NO20035627D0 (no) Farmasöytisk formulering
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20025805L (no) Farmasöytisk preparat
NO20033162L (no) Farmasöytisk tablett omfattende paroksetinmesylat
DK1390063T3 (da) Farmaceutisk doseringsform af amorft nelfinavir-mesylat
TR200400375T3 (tr) Taksanlarin sabit araliklarla dozlanmasi
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
FR2810862B1 (fr) Ensemble de tables gigognes
NO20041236L (no) Farmasoytisk formulering
UA5530S (uk) Таблетка фармацевтична
SE0102069D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application